Outcome
HLH, death
The primary assessment was the overall response rate (ORR) to ruxolitinib treatment, which included the proportion of patients achieving complete response (CR), partial response (PR), and improvement in HLH measures. The safety and tolerability of ruxolitinib treatment, survival at 2 months from the first dose of ruxolitinib, time to response, interval to achieve the best response, changes in pharmacodynamic biomarkers, such as inflammatory cytokines, between baseline and post-treatment, and the cause of death, were also collected and analyzed.